IN8bio's Leukemia Cell Therapy Shows Durable Response

  • IN8bio Inc INAB provided a clinical update from the ongoing Phase 1 trial of INB-100, an allogeneic or donor-derived, gamma-delta T cell therapeutic candidate in development for patients with high-risk leukemias undergoing haploidentical hematopoietic stem cell transplant (HSCT). 
  • "We are excited about the early signals of long-term durable responses from gamma-delta T cell therapy in these high-risk AML patients with complex cytogenetics," said Trishna Goswami, Chief Medical Officer of IN8bio. 
  • "Despite the up to 51% anticipated one-year relapse rate of the patients enrolled in the trial, all three remain alive and disease free for more than one-year post-transplant."
  • The Phase 1 trial continues to show positive clinical trends, with the first three patients remaining alive and progression-free. 
  • Despite multiple cytogenetic abnormalities and a high risk of relapse, these patients remain in remission 26.5, 24.2, and 12.5 months post-transplant, respectively. 
  • Immune system reconstitution at six months post-treatment demonstrates continued normal function, including observed elevations in T cells, B cells, and gamma-delta T cells. 
  • No treatment-emergent serious adverse events (SAEs) have been observed. 
  • The clinical trial is ongoing and additional patients have been recruited, with updated data expected in late 2022.
  • Price Action: INAB shares are up 20.04% at $2.65 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!